What are phase 1 clinical trials?

Promising anti-cancer drugs are tested in patients for the first time in phase 1 trials. These trials aim to determine the optimal dose of drugs for more advanced clinical trials. The primary focus of these trials is to determine the relationship between drug effects and drug dose. For a number of reasons, including the variable dose of drug tested, the chances of tumour shrinkage in such trials are low. Patients should not enrol in these trials in the expectation of the drug shrinking their tumour. However, if a patient’s tumour is controlled by the trial drug, the trial drug will be made available to them until such time as they or their doctors decide that drug treatment should be stopped.

Phase 1 trials may be suitable for cancer patients who are:

  • Fit and well
  • Have a cancer which is incurable by standard treatment
  • Wish to participate in research about developing new anti-cancer drugs
  • A trial in their specific cancer type is not currently available in Victoria/Australia

 

Available phase 1 clinical trials

Below is a list of clinical trials which are open at the Austin Hospital and certain other hospitals in Melbourne. The phase 1 trials unit at the Austin Hospital is headed by Dr Hui Gan and is comprised of a group of dedicated doctors, nurses, study coordinators and administrators. 

If a patient wishes to be considered for a trial at Austin Hospital, please forward a referral from their local doctor or oncologist to the phase 1 unit, Austin Hospital, 145 Studley Road, Heidelberg, Melbourne. A fax sent to 9457 6698 with the following information will be sufficient for the phase 1 Unit to organise an appointment within 1-2 weeks:

  • Name, date of birth, address and phone number of the patient
  • A brief history of the cancer treatment received to date
  • The referring doctor’s contact details and provider number

If a patient wishes to be considered for trials at Northern Hospital please contact Linda Harrison.  Ph 8405 2099

Current phase 1 clinical trials
 
Study number
Tumour types
Experimental agent
Administration
Recruitment status
Eligible criteria
Health Service
NOTCH M18-002
Newly diagnosed 
pancreatic cancer
Monoclonal antibody against 
Delta-like 4 ligand (DLL4) in 
combination with standard 
chemotherapy
TBA
Currently 
recruiting
See below
Austin 
Hospital
E7080
Colorectal only
A multikinase inhibitor, as 
second line therapy for 
irinotecan naive patients
Oral daily
Currently 
recruiting
See below
Northern 
Hospital
GSK2118436 and 
GSK1120212
Melanoma
BRAK and MEK inhibitors
Oral
Recurrent 
recruiting
See below
Austin 
Hospital
HMPL-504
Advanced 
malignancies
C-met inhibitor
Oral daily
Recurrent 
recruiting
See below
Austin 
Hospital
Avipep
TAG-72 positive 
ovarian and 
prostate cancer
124 I-PEG-AVP0458 diabody
Single IV 
administration
Recurrent 
recruiting
See below
Austin 
Hospital
NY-ESO-1
Melanoma
recNY-ESO-1 + AS15 
antigen-specific cancer 
immunotherapeutic
Complex
Recurrent 
recruiting
See below
Austin 
Hospital

 

print text size increase